These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
260 related items for PubMed ID: 19136028
1. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. Sass MB, Lorenz AN, Green RL, Coleman RA. J Neurosci Methods; 2009 Apr 15; 178(2):366-77. PubMed ID: 19136028 [Abstract] [Full Text] [Related]
2. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK. J Neurochem; 2009 Jul 15; 110(1):208-19. PubMed ID: 19457126 [Abstract] [Full Text] [Related]
3. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats. Miwa H, Kubo T, Suzuki A, Kondo T. Neurosci Lett; 2006 Jun 19; 401(1-2):146-9. PubMed ID: 16600504 [Abstract] [Full Text] [Related]
4. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Lev N, Melamed E, Offen D. Neurosci Lett; 2006 May 15; 399(1-2):27-32. PubMed ID: 16584840 [Abstract] [Full Text] [Related]
6. Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis. Alberio T, Bossi AM, Milli A, Parma E, Gariboldi MB, Tosi G, Lopiano L, Fasano M. FEBS J; 2010 Dec 15; 277(23):4909-19. PubMed ID: 20977677 [Abstract] [Full Text] [Related]
7. Alpha-synuclein nitration and autophagy response are induced in peripheral blood cells from patients with Parkinson disease. Prigione A, Piazza F, Brighina L, Begni B, Galbussera A, Difrancesco JC, Andreoni S, Piolti R, Ferrarese C. Neurosci Lett; 2010 Jun 14; 477(1):6-10. PubMed ID: 20399833 [Abstract] [Full Text] [Related]
10. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy. Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM. Neuroscience; 2011 Dec 29; 199():303-17. PubMed ID: 22056602 [Abstract] [Full Text] [Related]
12. A cell-based model of alpha-synucleinopathy for screening compounds with therapeutic potential of Parkinson's disease. Zhao DL, Zou LB, Zhou LF, Zhu P, Zhu HB. Acta Pharmacol Sin; 2007 May 15; 28(5):616-26. PubMed ID: 17439717 [Abstract] [Full Text] [Related]
18. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease. Witt SN, Flower TR. FEMS Yeast Res; 2006 Dec 15; 6(8):1107-16. PubMed ID: 17156009 [Abstract] [Full Text] [Related]
20. Convergent roles of alpha-synuclein, DA metabolism, and the ubiquitin-proteasome system in nigrostriatal toxicity. Fornai F, Lazzeri G, Bandettini Di Poggio A, Soldani P, De Blasi A, Nicoletti F, Ruggieri S, Paparelli A. Ann N Y Acad Sci; 2006 Aug 15; 1074():84-9. PubMed ID: 17105905 [Abstract] [Full Text] [Related] Page: [Next] [New Search]